digestive enzymes on glp 1 GLP-1 Nutritional Support Bundle Digestive Enzymes (90)

These trends suggest that GLP-1s are reshaping treatment patterns most significantly in markets where few alternatives exist and where their effectiveness is increasingly valued

A retrospective analysis of 105,000+ patients revealed: 40% lower OSA risk with tirzepatide (Zepbound) or semaglutide (Wegovy) vs non-AOM users Lower OSA incidence: 3.12% vs 12.56% Comparable impact between tirzepatide and semaglutide, with tirzepatide showing a slight edge after 6 months This study highlights the potential for AOMs to address obesity and OSA, supporting broader healthcare value through comorbidity reduction

Patients typically experience a 15-20% reduction in weight.

GLP-1 receptor agonist clinical trials surge, with semaglutide leading the way in obesity and type 2 diabetes treatmen

Antioxidant plant compounds supporting overall health

GLP-1 compounding faces legal challenges, evolving FDA rules, and heightened enforcement risks.